From: Paraoxonase-1 is related to inflammation, fibrosis and PPAR delta in experimental liver disease
 | Control group No CCl4 | CCl4 administration groups | Recovery groups CCl4 withdrawal | |||
---|---|---|---|---|---|---|
 |  | 6 weeks | 8 weeks | 12 weeks | 1 week | 2 weeks |
Collagen (%) | 0.22 (0.04) | 0.97 (0.31)a | 0.47 (0.06)a | 3.6 (0.3)a, e, h | 0.67 (0.09)a | 0.73 (0.16)a |
α-smooth muscle actin staining (%) | 0.109 (0.02) | 1.2 (0.3)b | 0.41 (0.07)b | 1.8 (0.5)b, g | 0.21 (0.03)a, d | 0.11 (0.02)d, i |
Aspartate aminotransferase (μkat/L) | 2.0 (0.2) | 5.9 (1.2)a | 5.4 (1.0)a | 25.0 (7.7)a, c, f | 2.3 (0.4)d | 2.0 (0.3)d |
Cholesterol (mmol/L) | 0.94 (0.07) | 0.70 (0.09)a | 0.78 (0.15) | 1.08 (0.14)c | 1.00 (0.15) | 1.12 (0.95) |
Triglycerides (mmol/L) | 2.65 (0.41) | 0.63 (0.08)b | 0.56 (0.06)b | 0.72 (0.18)b | 1.08 (0.13)b | 0.89 (0.13)b |